It is used to slow down the loss of walking ability in symptomatic pediatric patients from the age group of 3 years and above who suffer from late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease.
These patients lack the tripeptidyl peptidase-1 enzyme (TPP1) in their central nervous system (CNS).
cerliponase alfa (Brineura) is infused directly into the patient’s brain bypassing the blood brain barrier through a device called an intraventricular device.
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak with a healthcare professional.
Generic : cerliponase alfa